MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel.

PubWeight™: 0.78‹?›

🔗 View Article (PMID 27986684)

Published in Clin Infect Dis on December 16, 2016

Authors

Ross D Cranston1, Javier R Lama2, Barbra A Richardson3,4, Alex Carballo-Diéguez5, Ratiya Pamela Kunjara Na Ayudhya6, Karen Liu4, Karen B Patterson4, Cheng-Shiun Leu5, Beth Galaska6, Cindy E Jacobson6, Urvi M Parikh1, Mark A Marzinke7, Craig W Hendrix7, Sherri Johnson8, Jeanna M Piper9, Cynthia Grossman10, Ken S Ho1, Jonathan Lucas8, Jim Pickett11, Linda-Gail Bekker12, Suwat Chariyalertsak13, Anupong Chitwarakorn14, Pedro Gonzales2, Timothy H Holtz14,15, Albert Y Liu16, Kenneth H Mayer17, Carmen Zorrilla18, Jill L Schwartz19, James Rooney20, Ian McGowan1, MTN-017 Protocol Team

Author Affiliations

1: University of Pittsburgh, Pennsylvania, USA.
2: Asociación Civil Impacta Salud y Educación, Lima, Peru.
3: Department of Biostatistics, University of Washington, Box 359909, Seattle, WA, USA.
4: Fred Hutchinson Cancer Research Center-Statistical Center for HIV/AIDS Research and Prevention, Seattle, Washington, USA.
5: New York State Psychiatry Institute and Columbia University, New York, USA.
6: Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA.
7: Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
8: FHI 360, Durham, North Carolina, USA.
9: National Institute of Allergy and Infectious Disease/DAIDS, Rockville, MD, USA..
10: National Institute of Mental Health, Bethesda, Maryland, USA.
11: AIDS Foundation of Chicago, Illinois, USA.
12: Desmond Tutu HIV Centre, University of Cape Town, South Africa.
13: Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
14: Thailand Ministry of Public Health-US Centers for Disease Control and Prevention Collaboration, Bangkok, Thailand.
15: Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
16: Bridge HIV, San Francisco Department of Public Health, California, USA.
17: Fenway Institute, Boston, Massachusetts, USA.
18: Department of Obstetrics and Gynecology, University of Puerto Rico School of Medicine, San Juan, USA.
19: CONRAD/Eastern Virginia Medical School, Arlington, Virginia, USA.
20: Gilead Sciences, Foster City, California, USA.

Articles by these authors

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis (2014) 2.71

HIV incidence, risk factors, and motivation for biomedical intervention among gay, bisexual men, and transgender persons in Northern Thailand. PLoS One (2011) 1.28

Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men. PLoS One (2014) 1.09

Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis. Antimicrob Agents Chemother (2015) 0.99

The risk of stable partnerships: associations between partnership characteristics and unprotected anal intercourse among men who have sex with men and transgender women recently diagnosed with HIV and/or STI in Lima, Peru. PLoS One (2014) 0.90

Acceptability and feasibility of HIV self-testing among men who have sex with men in Peru and Brazil. Int J STD AIDS (2015) 0.89

High Prevalence and Genotype Diversity of Anal HPV Infection among MSM in Northern Thailand. PLoS One (2015) 0.84

Client and provider perspectives on new HIV prevention tools for MSM in the Americas. PLoS One (2015) 0.84

Cytological Anal Squamous Intraepithelial Lesions Associated with Anal High-Risk Human Papillomavirus Infections among Men Who Have Sex with Men in Northern Thailand. PLoS One (2016) 0.79

Using conjoint analysis to determine the impact of product and user characteristics on acceptability of rectal microbicides for HIV prevention among Peruvian men who have sex with men. Sex Transm Infect (2015) 0.78

Sexual Orientation, Gender Identity and Perceived Source of Infection Among Men Who Have Sex with Men (MSM) and Transgender Women (TW) Recently Diagnosed with HIV and/or STI in Lima, Peru. AIDS Behav (2016) 0.77

Partner-Level Factors Associated with Insertive and Receptive Condomless Anal Intercourse Among Transgender Women in Lima, Peru. AIDS Behav (2016) 0.75

Validation of the 'drinking expectancy questionnaire for men who have sex with men' in Peru. Drug Alcohol Rev (2015) 0.75

Detectable Tenofovir Levels in Breast-Feeding Infants of Mothers Exposed to Topical Tenofovir. Antimicrob Agents Chemother (2016) 0.75

Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model. Antimicrob Agents Chemother (2016) 0.75

Tuberculosis and Healthcare Workers in Underresourced Settings. Clin Infect Dis (2016) 0.75

Viral Suppression Levels in Men Who Have Sex With Men and Transgender Women With Newly Diagnosed HIV and Alcohol Use Disorder in Peru: Results From a Randomized, Double-Blind, Placebo-Controlled Trial Using Oral Naltrexone. J Acquir Immune Defic Syndr (2022) 0.75

Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052. PLoS One (2017) 0.75

Association of cytologic grade of anal "Pap" smears with viral loads of human papillomavirus types 16, 18, and 52 detected in the same specimens from men who have sex with men. J Clin Virol (2016) 0.75

Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men. AIDS Behav (2017) 0.75

Brief Participant-Centered Convergence Interviews Integrate Self-Reports, Product Returns, and Pharmacokinetic Results to Improve Adherence Measurement in MTN-017. AIDS Behav (2017) 0.75

Are participants concerned about privacy and security when using short message service to report product adherence in a rectal microbicide trial? J Am Med Inform Assoc (2017) 0.75

Factors Supporting and Hindering Adherence to Rectal Microbicide Gel Use with Receptive Anal Intercourse in a Phase 2 Trial. AIDS Behav (2017) 0.75

High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women. PLoS One (2017) 0.75